ArticleBrain, behavior, & immunity - health2026
Identification of autoantibodies against L1CAM in patients with schizophrenia.
Article in Brain, behavior, & immunity - health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synaptic autoantibodies have been implicated in the pathophysiology of a subset of schizophrenia cases. The identification of novel autoantibodies in schizophrenia may therefore provide insights into previously unrecognized disease mechanisms. Here, we report the presence of autoantibodies against L1 cell adhesion molecule (L1CAM), a membrane protein expressed in neurons that contributes to cell adhesion and synapse formation. Using a cell-based assay, we analyzed 387 patients with schizophrenia and 362 healthy controls. Anti-L1CAM autoantibodies were detected in two patients with schizophrenia but not in healthy controls, and were also identified in the cerebrospinal fluid (CSF). Analysis using L1CAM deletion constructs indicated that the Ig1 domain of L1CAM is a major target of these autoantibodies. Administration of purified IgG from these patients into the CSF of mice was associated with impaired cognitive performance. Patients positive for anti-L1CAM autoantibodies also exhibited marked cognitive deficits. Together, these findings suggest that anti-L1CAM autoantibodies may be associated with disease mechanisms in a small subset of schizophrenia cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.